Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DT Clear all
Recruiting Phase 2 Interventional

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT04216524
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Mercaptopurine, Methotrexate, Methylprednisolone, Prednisone, Rituximab, Tagraxofusp-erzs, Venetoclax, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD

NCT05717439
View directory record Official record
Conditions
PTSD, Generalized Anxiety Disorder, Major Depressive Disorder
Interventions
CAPS-5-R, Senseye DT
Diagnostic Test
Lead sponsor
Senseye, Inc.
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Aurora, Colorado • Meridian, Idaho • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 3, 2026, 5:01 AM EDT
Suspended Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

NCT06620302
View directory record Official record
Conditions
Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Childhood Fibrolamellar Carcinoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Fibrolamellar Carcinoma, Refractory Malignant Solid Neoplasm
Interventions
Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan
Biological · Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 39 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

NCT01482052
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
meningococcal meningitis conjugate vaccine, quadrivalent
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Health Intervention to Support Opioid Use Disorder Treatment

NCT03842384
View directory record Official record
Conditions
Opioid Use Disorder, Treatment Adherence
Interventions
iENDURE
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Sep 3, 2026, 5:01 AM EDT
Recruiting Not applicable Interventional

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

NCT06298734
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer, Advanced Melanoma
Interventions
Exercise Program, Diet Program
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors

NCT01151384
View directory record Official record
Conditions
Solid Tumors
Interventions
LE-DT
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2011 · Synced Sep 3, 2026, 5:01 AM EDT
Active, not recruiting Not applicable Interventional

Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer

NCT06019988
View directory record Official record
Conditions
Breast Cancer, Social Determinants of Health (SDOH)
Interventions
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 5:01 AM EDT
Withdrawn Phase 1 Interventional

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

NCT05720988
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Tagraxofusp-erzs
Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Women Engaging in Quitting Smoking Together (WE QUIT)

NCT02051803
View directory record Official record
Conditions
Smoking Cessation
Interventions
Distress Tolerance Treatment for Weight Concern (DT-W), Health Education (HE)
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Sep 3, 2026, 5:01 AM EDT
Completed No phase listed Observational

SUSTAIN-IT: Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support?

NCT02568930
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
60 Years to 80 Years
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Orlando, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

NCT01655693
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Doxorubicin 20 mg/m2, Doxorubicin 30 mg/m2, Best Standard of Care
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
Canton, Ohio • Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes

NCT02469233
View directory record Official record
Conditions
Mental Disorders
Interventions
Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 3, 2026, 5:01 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

JIT: Effect of Pain on DT in TMD

NCT06659991
View directory record Official record
Conditions
Temporomandibular Disorder (TMD)
Interventions
alcohol condition, control condition
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

NCT00414635
View directory record Official record
Conditions
HIV Infections
Interventions
Intermitent Dosing
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 3, 2026, 5:01 AM EDT
Completed No phase listed Observational

Arterial Pressure vs. TE Echo dp/dt

NCT04726852
View directory record Official record
Conditions
Myocardial Contraction
Interventions
Concurrent comparison
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes

NCT04154631
View directory record Official record
Conditions
Sleep Disorder, Circadian Dysregulation
Interventions
Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C), Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C), Usual Care Delayed Treatment
Behavioral · Other
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Concord, California • Fairfield, California • Goleta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 3, 2026, 5:01 AM EDT
Active, not recruiting Not applicable Interventional

Study of Poetic Dignity Therapy for Sexual and Gender Minority Patients With Cancer

NCT06293456
View directory record Official record
Conditions
End of Life
Interventions
Dignity Therapy
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

NCT02471716
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor
Interventions
FPA008
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Sep 3, 2026, 5:01 AM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 3, 2026, 5:01 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT01602315
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
BYL719 as film-coated (FC) whole tablets, BYL719 as dispersible tablets (DT), cetuximab, BYL719 drink suspension
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 3, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atlas of Retinal Imaging in Alzheimer's Study

NCT03862222
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
Other · Diagnostic Test · Genetic
Lead sponsor
University of Rhode Island
Other
Eligibility
55 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 3, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

NCT02066181
View directory record Official record
Conditions
Desmoid Fibromatosis
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Sorafenib Tosylate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
149
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arroyo Grande, California + 79 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 3, 2026, 5:01 AM EDT
Active, not recruiting No phase listed Observational

Destination Therapy Post Approval Study

NCT03681210
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
HeartWare Ventricular Assist Device
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Little Rock, Arkansas • San Diego, California • San Francisco, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 3, 2026, 5:01 AM EDT